

IN THE CLAIMS

Delete all Claims 19-25. Add the following Claims 26-32.

26. Process for the production of a dimeric, biologically active Transforming Growth Factor type  $\beta$ 2 (TGF- $\beta$ 2) or  $\beta$ 3 (TGF- $\beta$ 3), or a salt thereof, comprising treating the denatured monomeric form of said TGF- $\beta$ 2 or  $\beta$ 3 with a folding buffer consisting essentially of glutathione in its reduced form and an organic solvent which is DMSO (Dimethylsulfoxide) or DMF (Dimethylformamide) or a mixture of DMSO and DMF; thereby permitting folding of the monomeric TGF- $\beta$ 2 or  $\beta$ 3 into the spatial conformation which is associated with the biological activity, while retaining said monomer in a soluble form.

27. The process according to claim 26 in which DMSO is used at a concentration of about 30% to about 50% (vol/vol).

28. The process according to claim 26 in which DMF is used at a concentration of 40% (vol/vol).

29. The process according to claim 26 wherein the organic solvent is a mixture of DMSO and DMF and the mixture is used in a concentration of 10% to about 50% (vol/vol).

30. The process according to claim 26 in which the buffer has a pH of about 8.5 to about 10.

31. The process according to claim 26 in which the buffer has a temperature of about 0°C to about 40°C.

32. The process according to claim 26 in which the reduced glutathione is used in a concentration of about 1 mM to 100 mM.